Ocumension completes first patient enrollment in Phase III China trial of dry eye drug OT-202

• Ocumension Therapeutics completed first patient enrollment in a China Phase III trial of OT-202 for moderate to severe dry eye disease.
• No new Phase III results were presented; the update marked the start of late-stage testing.
• Earlier Phase II results were published in Ophthalmology, with the study meeting its primary endpoints in March 2024.
• OT-202 is a dual-target inhibitor intended to reduce inflammation, supporting a potential differentiated treatment profile if Phase III succeeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308722), on August 31, 2026, and is solely responsible for the information contained therein.